← Leaderboards
Samuel C Mok
Brigham And Women'S Hospital
$7,260,442
Attributed
$11,080,214
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,080,214 · 8
By mechanism
R01$6,387,681 · 5
U01$1,979,214 · 1
R33$1,842,255 · 1
P50$871,064 · 1
Top collaborators
- Michael Birrer8 shared
- Deepak Nagrath5 shared
- Anil K Sood5 shared
- Sammy Ferri-Borgogno2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Juan Carlos Celedon$24,953,784
- Nitin Joshi$2,325,703
- Jeffery M Drazen$387,914
- Jennifer L Hunt$1,517,912
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryNeoplasm MetastasisBaseComparative Genomic HybridizationSpecimenTumorCancer Cell LineCancer TherapyMalignant NeoplasmsCancer EtiologyOvarian NeoplasmGynecologic Oncology GroupProtocols DocumentationSerousNeoplastic CellCancer PatientNew Therapeutic TargetCarcinomaCancer CellClinical TrialsDiagnosisDna Copy NumberStromal CellsUnited States
Grant awards (31)
3D Spatial Multi-Omics Profiling of Ovarian Cancer$974,644
U01 · FY2025 · CA · contact PI
3D Spatial Multi-Omics Profiling of Ovarian Cancer$1,004,570
U01 · FY2024 · CA · contact PI
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$462,390
R01 · FY2022 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$471,827
R01 · FY2021 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$471,827
R01 · FY2020 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$457,671
R01 · FY2019 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$485,829
R01 · FY2018 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$226,535
R01 · FY2017 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$145,785
R01 · FY2017 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$372,052
R01 · FY2016 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$372,052
R01 · FY2015 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$360,890
R01 · FY2014 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$390,552
R01 · FY2013 · CA
Prognostic markers for ovarian cancer$291,367
R01 · FY2013 · CA · contact PI
Prognostic markers for ovarian cancer$309,964
R01 · FY2012 · CA · contact PI
Prognostic markers for ovarian cancer$287,595
R01 · FY2011 · CA · contact PI
Prognostic markers for ovarian cancer$319,550
R01 · FY2010 · CA · contact PI
Prognostic markers for ovarian cancer$319,550
R01 · FY2009 · CA · contact PI
Genetic Changes in Early Stage Ovarian Cancer$222,918
P50 · FY2008 · CA · contact PI
Genetic Changes in Early Stage Ovarian Cancer$221,167
P50 · FY2007 · CA · contact PI
Prognostic markers for ovarian cancer$410,748
R33 · FY2006 · CA · contact PI
Genetic Changes in Early Stage Ovarian Cancer$145,869
P50 · FY2006 · CA · contact PI
Prognostic markers for ovarian cancer$57,137
R33 · FY2006 · CA · contact PI
Prognostic markers for ovarian cancer$468,584
R33 · FY2005 · CA
Genetic Changes in Early Stage Ovarian Cancer$141,154
P50 · FY2005 · CA
Prognostic markers for ovarian cancer$451,639
R33 · FY2004 · CA
Genetic Changes in Early Stage Ovarian Cancer$139,956
P50 · FY2004 · CA
Prognostic markers for ovarian cancer$454,147
R33 · FY2003 · CA
SIGNAL TRANSDUCTION MOLECULE IN OVARIAN CARCINOGENESIS$226,367
R01 · FY2001 · CA
SIGNAL TRANSDUCTION MOLECULE IN OVARIAN CARCINOGENESIS$219,770
R01 · FY2000 · CA
PAPILLARY SEROUS CARCINOMA OF THE PERITONEUM$196,108
R01 · FY2000 · CA